More Articles

For complex biosimilars in EU: drop clinical comparability Biosimilars/Research | Posted 15/03/2010

Clinical trials required by European regulators to compare biosimilar products with corresponding biologic brands are surplus to requirements and may even be a barrier for the development of biosim...

Daiichi Sankyo unit to sell generic drugs in Japan Generics/News | Posted 15/03/2010

Daiichi Sankyo Co. Ltd. said on 26 February 2010 it will set up a new subsidiary in April 2010 to produce and sell generic drugs in Japan, in – according to Mr Kazuhiro Shimamura in the Wall Street...

After generics slow down in 2013: into biosimilars Pharma News | Posted 12/03/2010

Large pharmaceutical companies are consolidating their generics operations in established markets and/or expanding into emerging ones through local acquisitions or partnerships, writes Ms Doris de...

Global generics: time for consolidation and expansion Pharma News | Posted 12/03/2010

The global generic drug industry has witnessed an almost decade-long sales euphoria. Volumes and sales growth of prescription generic drugs continued to increase in 2009. At the same time, large co...

IMS Health, BCC: Generics sales continue to climb Pharma News | Posted 12/03/2010

Over the 12 months that ended September 2009, global sales of generics grew by 7.7%, up from 3.6 % the year before, IMS Health reported. This compares with the 5.7% growth seen within the overall g...

New method for producing human-like glycosylated MAbs Biosimilars/Research | Posted 11/03/2010

As reported online on 28 February 2010 in Nature Chemical Biology, Professor Lai-Xi Wang, Professor Markus Aebi and colleagues describe a new bacterial method for producing homogeneous eukaryotic N...

GTC achieves high-level production of TG20, a biobetter anti-CD20 MAb with enhanced antibody-dependent cell-mediated cytotoxicity Biosimilars/News | Posted 11/03/2010

GTC Biotherapeutics announced on 1 March 2010 that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic g...

Glycosylation technologies for biosimilars and ‘biobetters’ Biosimilars/Research | Posted 10/03/2010

According to Mr Hans Baumeister and Mr Steffen Goletz of Glycotope, human cell lines providing a human glycosylation pattern – such as those of Crucell (PER.C6), Cevec (CAP) and Glycotope (GlycoExp...